Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.70 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.66 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | FAAH | O00519 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.55 |
| ▸ | RELA | Q04206 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20730105 | 0.94 | CHRNB2 (0.64) | CYP2C9CYP2C19CYP2D6CYP3A4CYP19A1 | |
| SCHEMBL9367178 | 0.93 | CHRNB2 (0.62) | CYP2C9CYP2C19CYP2D6CYP3A4CYP19A1 | |
| SCHEMBL30542607 | 0.93 | CHRNB2 (0.62) | CYP2C9CYP2C19CYP2D6CYP3A4CYP19A1 | |
| SCHEMBL3229561 | 0.93 | CHRNB2 (0.62) | CYP2C9CYP2C19CYP2D6CYP3A4CYP19A1 | |
| SCHEMBL19055583 | 0.93 | CHRNB2 (0.62) | CYP2C9CYP2C19CYP2D6CYP3A4CYP19A1 | |
| SCHEMBL4888697 | 0.93 | CHRNB2 (0.62) | CYP2C9CYP2C19CYP2D6CYP3A4CYP19A1 | |
| Hydrochloric Acid SCHEMBL29969480 | 0.91 | CHRNB2 (0.60) | CYP2C9CYP2C19CYP2D6CYP3A4CYP19A1 | |
| SCHEMBL30338591 | 0.90 | CHRNB2 (0.68) | CYP2C9CYP2C19CYP2D6CYP3A4CYP19A1 | |
| SCHEMBL171896 | 0.90 | CHRNB2 (0.68) | CYP2C9CYP2C19CYP2D6CYP3A4CYP19A1 | |
| SCHEMBL2270670 | 0.89 | KMT2A (0.67) | CYP2C9CYP2C19CYP2D6CYP3A4CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4318630-B1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS SECONDARY BATTERY | ASAHI CHEMICAL IND (JP) | 2025-10-22 | — | — | EP | disclosed |
| US-12199280-B2 | Non-aqueous secondary battery and non-aqueous electrolyte | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2025-01-14 | — | — | US | disclosed |
| EP-4415105-A2 | NON-AQUEOUS SECONDARY BATTERY AND NON-AQUEOUS ELECTROLYTE | Asahi Kasei Kabushiki Kaisha (JP) | 2024-08-14 | — | — | EP | disclosed |
| US-20240178452-A1 | Nonaqueous Electrolyte Solution and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2024-05-30 | — | — | US | disclosed |
| EP-4318630-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS SECONDARY BATTERY | Asahi Kasei Kabushiki Kaisha (JP) | 2024-02-07 | — | — | EP | disclosed |
| CN-117223143-A | Nonaqueous electrolyte and nonaqueous secondary battery | 旭化成株式会社 | 2023-12-12 | — | — | CN | disclosed |
| WO-2022203072-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS SECONDARY BATTERY | 旭化成株式会社 | 2022-09-29 | — | — | WO | disclosed |
| US-20220293929-A1 | Non-Aqueous Secondary Battery and Non-Aqueous Electrolyte | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2022-09-15 | — | — | US | disclosed |
| EP-4009398-A1 | NON-AQUEOUS SECONDARY BATTERY AND NON-AQUEOUS ELECTROLYTE | Asahi Kasei Kabushiki Kaisha (JP) | 2022-06-08 | — | — | EP | disclosed |
| CN-114342145-A | Nonaqueous secondary battery and nonaqueous electrolyte | 旭化成株式会社 | 2022-04-12 | — | — | CN | disclosed |
| US-20050215794-A1 | Copper-catalyzed formation of carbon heteroatom and carbon-carbon bonds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-09-29 | — | — | US | disclosed |
| US-6867298-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2005-03-15 | — | — | US | disclosed |
| CN-1518534-A | Copper-catalyzed carbon-heteroatom and carbon-carbon bond formation | 麻省理工学院 | 2004-08-04 | — | — | CN | disclosed |
| US-6759554-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2004-07-06 | — | — | US | disclosed |
| EP-1390340-A1 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20040019216-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-29 | — | — | US | disclosed |
| US-20030065187-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-04-03 | — | — | US | disclosed |
| WO-2002085838-A1 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-10-31 | — | — | WO | disclosed |
| EP-1212301-A1 | ARYLALKYLOXYALKYLAMINES AND ARYLALKYLTHIOALKYLAMINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016107-A1 | ARYLALKYLOXYALKYLAMINES AND ARYLALKYLTHIOALKYLAMINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215794-A1 | Copper-catalyzed formation of carbon heteroatom and carbon-carbon bonds | CBR3, ADH5, IDH1 | CYP2C9 287/4885CYP2C19 379/4885CYP2D6 126/4885 |
| US-20220293929-A1 | Non-Aqueous Secondary Battery and Non-Aqueous Electrolyte | CLK2, TYK2, CLK3 | CYP2C9 2711/4885CYP2C19 2909/4885CYP2D6 4271/4885 |
| US-20030065187-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | ADH5, CBR3, ALDH3A1 | CYP2C9 269/4885CYP2C19 351/4885CYP2D6 132/4885 |
| US-20040019216-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | ADH5, CBR3, ALDH3A1 | CYP2C9 269/4885CYP2C19 351/4885CYP2D6 132/4885 |
| US-12199280-B2 | Non-aqueous secondary battery and non-aqueous electrolyte | CLK2, TYK2, CLK3 | CYP2C9 2711/4885CYP2C19 2909/4885CYP2D6 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.